# Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib

> **NCT01910987** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 80 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** bortezomib (optimized retreatment)
- **DRUG:** dexamethasone (optimized retreatment)
- **DRUG:** bortezomib (standard retreatment)
- **DRUG:** dexamethasone (standard retreatment)

## Key facts

- **NCT ID:** NCT01910987
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910987, "Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01910987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*